CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore Astellas Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 7, 2025
Patent NumberGrant DateTitleTotal Oppositions
Jan 10, 2024Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer3
Jan 11, 2023Stable Pharmaceutical Composition For Oral Administration2
Jul 6, 2022Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer2
Aug 18, 2021Formulations Of Enzalutamide11
Dec 30, 2020Controlled Release Pharmaceutical Composition6
Sep 9, 2020Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer1
Nov 14, 2018Novel Fgfr3 Fusion Product2
Jan 24, 2018Controlled Release Pharmaceutical Composition4

Top competitors of Astellas Pharma

List of top competitors of Astellas Pharma based on patent oppositions.